Vixarelimab clinical trials
Also written KPL-716 and RG6536.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses vixarelimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses vixarelimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative ColitisCompletedPhase 1Genentech, Inc.NCT06693908Written as Vixarelimab
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)TerminatedPhase 2Genentech, Inc.NCT06137183Written as Vixarelimab
- A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung DiseaseTerminatedPhase 2Genentech, Inc.NCT05785624Written as Vixarelimab
- Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo NodularisCompletedPhase 2Genentech, Inc.NCT03816891Written as Vixarelimab
- A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic DiseasesCompletedPhase 2Genentech, Inc.NCT03858634Written as KPL-716
Codes
What other systems call vixarelimab · ClinicalTrials.gg INT018292
- UNII (FDA) W25GO3A75WVIXARELIMABOne source FDA
- NCI Thesaurus C174929VixarelimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | W25GO3A75W | VIXARELIMAB | One source FDA |
| NCI Thesaurus | C174929 | Vixarelimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.